Read about an AI-enabled personalized approach combining senolytics and stem cell rejuvenation presented at a global biotech forum for systemic longevity.
Key Takeaways
- Preclinical models reportedly showed mean lifespan extension exceeding seventy percent
- Company described a dual-target senolytic and stem cell rejuvenation strategy
- Collaborations were cited with the Buck Institute, Cedars-Sinai, UC San Diego, and University of Miami